Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

Overview of attention for article published in Respiratory Research, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 20 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 6,371 followers.

RT @NeumologiaPeru: 🔥🔥Preclinical development of a long-acting trivalent bispecific #nanobody targeting IL-5 for the treatment of #eosinoph…

23 Nov 2022

Reply Repost Favourite

🔥🔥Preclinical development of a long-acting trivalent bispecific #nanobody targeting IL-5 for the treatment of #eosinophilic #asthma 🫁🎯🏅💉 https://t.co/X38dHJ4FdW @doclip1 @DrCindyThamrin @abrahamalimd @MonaBafadhel @DocdelOlmo @ArchBronconeumo @CPorsbjer

23 Nov 2022

Reply Repost Favourite

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for ... - PubMed https://t.co/twzxwd9gRG ... bispecific IL-5-HSA Nb has the potential to be a next-generation therapeutic agent targeting IL-5 for the treatment of severe

21 Nov 2022

Reply Repost Favourite

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma https://t.co/8FXtOARhQT

20 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.